Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

This phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur–uracil (UFT®) with leucovorin (LV) combined with intravenous (i.v.) irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC). Patients received oral UF...

詳細記述

保存先:
書誌詳細
主要な著者: Delord, J-P, Bennouna, J, Artru, P, Perrier, H, Husseini, F, Desseigne, F, François, E, Faroux, R, Smith, D, Piedbois, P, Naman, H, Douillard, J Y, Bugat, R
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2007
主題:
Clinical Study
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360336/
https://ncbi.nlm.nih.gov/pubmed/17637682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603889
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料